Bridgebio Pharma Inc (BBIO)

10:59 AM

BridgeBio to present encaleret data at endocrinology congress By Investing.com - Investing.com South Africa

10:59 AM

09:24 AM

BridgeBio Pharma to Present Phase 3 Infigratinib Achondroplasia Trial Results at ECE 2026, Focusing on Annualized Growth Velocity in Children Aged 3-11 - geneonline.com

09:24 AM

08:37 AM

MSN Money - MSN

08:37 AM

07:35 AM

BridgeBio to unveil Phase 3 rare-disease trial results in Prague - Stock Titan

07:35 AM

07:31 AM

BridgeBio seesaws after settlement in Pfizer Vyndamax patent dispute (update) - MSN

07:31 AM

07:30 AM

BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE - Yahoo Finance

07:30 AM

03:14 AM

BBIO SEC FilingsBridgebio Pharma 10-K, 10-Q, 8-K Forms - Stock Titan

03:14 AM

May 04, 2026

[Form 4] BridgeBio Pharma, Inc. Insider Trading Activity - Stock Titan

May 04, 2026

May 04, 2026

Achondroplasia Pipeline Expands as 15+ Pharma Companies - openPR.com

May 04, 2026

May 04, 2026

BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026 - The Manila Times

May 04, 2026

May 04, 2026

New heart failure data on BridgeBio drug lands late-breaking ESC slot - Stock Titan

May 04, 2026

May 03, 2026

William Blair Initiates BridgeBio Pharma(BBIO.US) With Buy Rating - Moomoo

May 03, 2026

May 02, 2026

BridgeBio Pharma Inc. (BBIO): Billionaire Tom Steyer Admires Upside Potential of This Stock - Insider Monkey

May 02, 2026

May 01, 2026

BridgeBio gains amid report of settlement in Pfizer Vyndamax patent dispute - MSN

May 01, 2026

May 01, 2026

Vanguard Group Inc. Increases Stake in BridgeBio Pharma, Inc. $BBIO - MarketBeat

May 01, 2026

Apr 30, 2026

BridgeBio (BBIO) Q2 2025 Earnings Transcript - AOL.com

Apr 30, 2026

Apr 30, 2026

(BBIO) Volatility Zones as Tactical Triggers - Stock Traders Daily

Apr 30, 2026

Apr 30, 2026

BBOT SEC FilingsBridgeBio Oncology Therapeutics, Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 30, 2026

Apr 30, 2026

Truist Financial Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Raises Target Price to $102 - Moomoo

Apr 30, 2026

Apr 30, 2026

Truist Financial Keeps Their Buy Rating on BridgeBio Pharma (BBIO) - The Globe and Mail

Apr 30, 2026

Apr 30, 2026

BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET - The Manila Times

Apr 30, 2026

Apr 30, 2026

After the bell: BridgeBio schedules Q1 results and program update - Stock Titan

Apr 30, 2026

Apr 30, 2026

Is Attruby’s Accelerating Launch and Star-Studded Awareness Campaign Altering The Investment Case For BridgeBio Pharma (BBIO)? - Yahoo Finance

Apr 30, 2026

Apr 30, 2026

The Escalator: BridgeBio Oncology Therapeutics, Haleon, AstraZeneca and more - Medical Marketing and Media

Apr 30, 2026

Apr 29, 2026

BridgeBio: Attruby's Early Dominance Makes The Bull Case Hard To Ignore (NASDAQ:BBIO) - Seeking Alpha

Apr 29, 2026

Apr 29, 2026

BridgeBio rises after late-stage trial win for dwarfism therapy - MSN

Apr 29, 2026

Apr 29, 2026

BridgeBio Pharma Is Maintained at Buy by Truist Securities - Moomoo

Apr 29, 2026

Apr 29, 2026

BridgeBio earnings on deck: Can Attruby sustain rapid growth? By Investing.com - Investing.com South Africa

Apr 29, 2026

Apr 29, 2026

BridgeBio earnings on deck: Can Attruby sustain rapid growth? - Investing.com

Apr 29, 2026

Apr 29, 2026

Analysts Are Bullish on Top Healthcare Stocks: BridgeBio Pharma (BBIO), Wave Life Sciences (WVE) - The Globe and Mail

Apr 29, 2026

Apr 29, 2026

BBIO Maintained by Truist Securities -- Price Target Raised to $102 - GuruFocus

Apr 29, 2026

Apr 29, 2026

Truist Financial Issues Positive Forecast for BridgeBio Pharma (NASDAQ:BBIO) Stock Price - MarketBeat

Apr 29, 2026

Apr 29, 2026

BBIO Reiterated by HC Wainwright & Co. -- Price Target Maintained at $100 - GuruFocus

Apr 29, 2026

Apr 29, 2026

symbol__ Stock Quote Price and Forecast - CNN

Apr 29, 2026

Apr 29, 2026

H.C. Wainwright reiterates BridgeBio Pharma stock rating on stable Vyndamax outlook - Investing.com Canada

Apr 29, 2026

Apr 29, 2026

BridgeBio Pharma, Inc. $BBIO Holdings Lifted by Moody Aldrich Partners LLC - MarketBeat

Apr 29, 2026

Apr 29, 2026

HC Wainwright Predicts Weaker Earnings for BridgeBio Pharma - MarketBeat

Apr 29, 2026

Apr 29, 2026

Pictet Asset Management Holding SA Has $96.96 Million Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat

Apr 29, 2026

Apr 29, 2026

Teachers Retirement System of The State of Kentucky Buys 17,343 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat

Apr 29, 2026

Apr 28, 2026

BridgeBio launches ATTR-CM awareness campaign with Morgan Freeman By Investing.com - Investing.com South Africa

Apr 28, 2026

Apr 28, 2026

BridgeBio launches ATTR-CM awareness campaign with Morgan Freeman - Investing.com UK

Apr 28, 2026

Apr 28, 2026

BofA raises BridgeBio Pharma stock price target on Pfizer settlement clarity - Investing.com Canada

Apr 28, 2026

Apr 28, 2026

BridgeBio Oncology (Nasdaq: BBOT) details 2026 virtual meeting, board elections and auditor - Stock Titan

Apr 28, 2026

Apr 28, 2026

Raymond James reiterates BridgeBio stock rating on Vyndamax settlement By Investing.com - Investing.com Canada

Apr 28, 2026

Apr 28, 2026

Mizuho Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $106 - Moomoo

Apr 28, 2026

Apr 28, 2026

BBIO Reiterated by Mizuho -- Price Target Maintained at $106 - GuruFocus

Apr 28, 2026

Apr 28, 2026

Barclays sees Pfizer IP case progress as positive for BridgeBio stock - Investing.com Canada

Apr 28, 2026

Apr 28, 2026

Pfizer deals extend patent life for a top-selling rare disease drug - BioPharma Dive

Apr 28, 2026